Related Experiment Video
Updated: May 3, 2026
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Mileage matters: long-distance performance of CARs in multiple myeloma
Eric M Jurgens1, Saad Z Usmani1, Maximilian Merz2,3
1Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Abstract:
Targeting B-cell maturation antigen with chimeric antigen receptor (CAR) T-cells is a new standard of care in relapsed/refractory multiple myeloma (RRMM). However, long-term data have currently remained sparse. In a recent study published in the Journal for ImmunoTherapy of Cancer by Jin et al, authors reported on a large cohort of 141 patients with a median follow-up of 20.2 months. They found an overall response rate of 90.1% with 48.2% achieving a complete response. The median progression-free survival was 15.2 months, and the 4-year overall survival rate was 63.2%. In the current article, we summarize the published long-term data from clinically approved and investigational CAR T-cells for RRMM.
Insights
Chimeric antigen receptor (CAR) T-cell therapy shows promise for relapsed/refractory multiple myeloma (RRMM). Long-term data reveal high response rates and durable survival, establishing it as a new standard of care.
Area of Science:
- Oncology
- Immunotherapy
- Hematology
Background:
- B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cells are a new standard of care for relapsed/refractory multiple myeloma (RRMM).
- Long-term outcome data for BCMA-targeted CAR T-cell therapy in RRMM remain limited.
Purpose of the Study:
- To summarize and analyze published long-term data for CAR T-cells targeting BCMA in RRMM.
- To provide insights into the durability and long-term efficacy of this treatment modality.
Main Methods:
- A comprehensive review of published literature on BCMA-targeted CAR T-cells for RRMM.
- Analysis of data from a large cohort of 141 patients with a median follow-up of 20.2 months.
Main Results:
- An overall response rate (ORR) of 90.1% was observed, with 48.2% achieving complete response (CR).
- Median progression-free survival (PFS) was 15.2 months.
- The 4-year overall survival (OS) rate reached 63.2%.
Conclusions:
- BCMA-targeted CAR T-cell therapy demonstrates significant and durable efficacy in RRMM patients.
- These findings support the role of CAR T-cells as a long-term treatment option for RRMM.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
